一分钟看懂
这是一项关于肺癌的III 期研究，登记的药物或干预包括ZL-1310；Investigator's Choice of Therapy，当前状态为招募中。登记地点显示中国合肥、福州、厦门、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
ZL-1310；Investigator's Choice of Therapy · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Hospital · 合肥
- Fujian Cancer Hospital · 福州
- The First Affiliated Hospital of Xiamen University · 厦门
- Guangdong Provincial People's Hospital · 广州
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- Harbin Medical University Cancer Hospital · 黑龙江省
- Fourth Hospital of Hebei Medical University · 石家庄
- The First Affiliated Hospital of Zhengzhou University · 郑州
- Hubei Cancer Hospital · 武汉
- Hunan Cancer Hospital · 长沙
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School · 南京
- Jiangxi Cancer Hospital · 南昌
- Jilin Cancer Hospital · 长春
- The First Affiliated Hospital of Xi'an Jiaotong University · 西安
- Shandong Cancer Hospital · 济南
- Linyi Cancer Hospital · 临沂
- Shanghai Pulmonary Hospital · 上海
- Sichuan Cancer Hospital · 成都
- Zhejiang Cancer Hospital · 杭州
- Taizhou Hospital of Zhejiang Province · 台州
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
- Beijing Cancer Hospital · 北京
- Henan cancer Hospital · 郑州
公开的入选条件
- * Age \>/= 18 years, or considered an adult by local regulations, at the time of consent
- * Signed informed consent
- * Histologically or cytologically confirmed SCLC. Received 1L platinum-based systemic therapy and had documented disease progression during or after the most recent systemic therapy. Or received 2L tarlatamab is allowed.
- * Measurable disease according to RECIST v1.1 as assessed by the investigator.
- * Participants with a history of treated and stable or untreated and asymptomatic CNS metastases based on criteria per protocol.
- * Adequate organ and marrow function
- * Eastern Cooperative Group (ECOG) performance status of 0 or 1
- * Life expectancy of at least 3 months
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07218146；登记信息更新于 2026-09-14。